Sleep disturbances frequently drive the progression of neuropsychiatric and neurodegenerative conditions, yet measuring them objectively has historically required costly, inconvenient in-lab stays. Most consumer-grade wearables rely on secondary markers like movement or heart rate, often failing to capture the neurological complexity of sleep. The integration of Muse’s EEG hardware into the NeuLogiq system allows researchers to track slow waves, spindles, and K-complexes directly from a participant's home.

According to research published in SLEEP Advances, the Muse technology achieves 88–96% agreement with gold-standard polysomnography. By capturing trial-grade sleep architecture in a home environment, the platform aims to reduce patient burden while increasing the frequency of data collection. Tina Sampath, CEO of Cumulus, noted that the move is designed to shift CNS clinical development away from subjective reporting toward more reliable, multi-modal longitudinal data. The companies plan to demonstrate these integrated capabilities at the Alzheimer's Association International Conference in London, scheduled for July 12–15.